WNT16 is Robustly Increased by Oncostatin M in Mouse Calvarial Osteoblasts and Acts as a Negative Feedback Regulator of Osteoclast Formation Induced by Oncostatin M

Background Bone loss is often observed adjacent to inflammatory processes. The WNT signaling pathways have been implicated as novel regulators of both immune responses and bone metabolism. WNT16 is important for cortical bone mass by inhibiting osteoclast differentiation, and we have here investigated the regulation of WNT16 by several members of the pro-inflammatory gp130 cytokine family. Methods The expression and regulation of Wnt16 in primary murine cells were studied by qPCR, scRNAseq and in situ hybridization. Signaling pathways were studied by siRNA silencing. The importance of oncostatin M (OSM)-induced WNT16 expression for osteoclastogenesis was studied in cells from Wnt16-deficient and wild-type mice. Results We found that IL-6/sIL-6R and OSM induce the expression of Wnt16 in primary mouse calvarial osteoblasts, with OSM being the most robust stimulator. The induction of Wnt16 by OSM was dependent on gp130 and OSM receptor (OSMR), and downstream signaling by the SHC1/STAT3 pathway, but independent of ERK. Stimulation of the calvarial cells with OSM resulted in enhanced numbers of mature, oversized osteoclasts when cells were isolated from Wnt16 deficient mice compared to cells from wild-type mice. OSM did not affect Wnt16 mRNA expression in bone marrow cell cultures, explained by the finding that Wnt16 and Osmr are expressed in distinctly different cells in bone marrow, nor was osteoclast differentiation different in OSM-stimulated bone marrow cell cultures isolated from Wnt16−/- or wild-type mice. Furthermore, we found that Wnt16 expression is substantially lower in cells from bone marrow compared to calvarial osteoblasts. Conclusion These findings demonstrate that OSM is a robust stimulator of Wnt16 mRNA in calvarial osteoblasts and that WNT16 acts as a negative feedback regulator of OSM-induced osteoclast formation in the calvarial bone cells, but not in the bone marrow.

[1]  Xiaoqin Yang,et al.  WNT16 is upregulated early in mouse TMJ osteoarthritis and protects fibrochondrocytes against IL-1β induced inflammatory response by regulation of RUNX2/MMP13 cascade. , 2020, Bone.

[2]  S. Movérare-Skrtic,et al.  Wnt16 Overexpression in Osteoblasts Increases the Subchondral Bone Mass but has no Impact on Osteoarthritis in Young Adult Female Mice , 2020, Calcified Tissue International.

[3]  Joshua D. Welch,et al.  A Wnt-mediated transformation of the bone marrow stromal cell identity orchestrates skeletal regeneration , 2020, Nature Communications.

[4]  B. Alman,et al.  Erythromyeloid progenitors give rise to a population of osteoclasts contributing to bone homeostasis and repair , 2019, Nature Cell Biology.

[5]  U. Lerner.  Role of Interleukins on Physiological and Pathological Bone Resorption and Bone Formation: Effects by Cytokines in The IL-1 and IL-2 Families , 2020 .

[6]  R. Baron,et al.  Sfrp4 repression of the Ror2/Jnk cascade in osteoclasts protects cortical bone from excessive endosteal resorption , 2019, Proceedings of the National Academy of Sciences.

[7]  U. Lerner,et al.  Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor , 2019, Front. Immunol..

[8]  R. Satija,et al.  The bone marrow microenvironment at single-cell resolution , 2019, Nature.

[9]  T. Martin,et al.  IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis , 2019, The Journal of Biological Chemistry.

[10]  R. Baron,et al.  Mesenchymal Cell‐Derived Juxtacrine Wnt1 Signaling Regulates Osteoblast Activity and Osteoclast Differentiation , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  K. Ho,et al.  Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade , 2019, Annals of the rheumatic diseases.

[12]  S. Movérare-Skrtic,et al.  WNT16 overexpression partly protects against glucocorticoid-induced bone loss. , 2018, American journal of physiology. Endocrinology and metabolism.

[13]  K. Sjögren,et al.  Inducible Wnt16 inactivation: WNT16 regulates cortical bone thickness in adult mice , 2018, The Journal of endocrinology.

[14]  P. Denormandie,et al.  Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. , 2017, JCI insight.

[15]  G. Müller-Newen,et al.  Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Zeitschrift für Gastroenterologie.

[16]  A. Blumenthal,et al.  WNT ligands contribute to the immune response during septic shock and amplify endotoxemia-driven inflammation in mice. , 2017, Blood advances.

[17]  J. Delaissé,et al.  Coupling of Bone Resorption and Formation in Real Time: New Knowledge Gained From Human Haversian BMUs , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  R. Owens,et al.  Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Nature Medicine.

[19]  F. Dell’Accio,et al.  WNT16 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis , 2016, Annals of the rheumatic diseases.

[20]  G. Smyth,et al.  Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass* , 2016, The Journal of Biological Chemistry.

[21]  Brian J. Stevenson,et al.  Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. , 2016, The New England journal of medicine.

[22]  S. Khosla,et al.  Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  J. Gustafsson,et al.  The bone-sparing effects of estrogen and WNT16 are independent of each other , 2015, Proceedings of the National Academy of Sciences.

[24]  M. Sweet,et al.  Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury , 2015, Fibrogenesis & tissue repair.

[25]  H. Hermanns.  Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. , 2015, Cytokine & growth factor reviews.

[26]  C. Ohlsson,et al.  The WNT system: background and its role in bone , 2015, Journal of internal medicine.

[27]  R. Baron,et al.  A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures. , 2015, BoneKEy reports.

[28]  S. Mohan,et al.  Role of WNT16 in the regulation of periosteal bone formation in female mice. , 2015, Endocrinology.

[29]  P. Layrolle,et al.  Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury. , 2015, The American journal of pathology.

[30]  R. Baron,et al.  Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures , 2014, Nature Medicine.

[31]  D. Graves,et al.  Non-canonical Wnt4 prevents skeletal aging and inflammation by inhibiting NF-κB , 2014, Nature Medicine.

[32]  C. Richards.  The Enigmatic Cytokine Oncostatin M and Roles in Disease , 2013, ISRN inflammation.

[33]  U. Lerner,et al.  The role of cytokines in inflammatory bone loss , 2013, Immunological investigations.

[34]  R. Gibbs,et al.  WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. , 2013, The New England journal of medicine.

[35]  M. Amling,et al.  Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin , 2013, The Journal of cell biology.

[36]  Roland Baron,et al.  WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.

[37]  U. Lerner,et al.  Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2. , 2013, Bone.

[38]  Georg Schett,et al.  Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment , 2012, Nature Reviews Rheumatology.

[39]  Nina Jones,et al.  Teaching an old dogma new tricks: twenty years of Shc adaptor signalling. , 2012, The Biochemical journal.

[40]  David M. Evans,et al.  WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk , 2012, PLoS genetics.

[41]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[42]  Daniel L. Koller,et al.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.

[43]  T. Martin,et al.  Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis , 2012, Nature Medicine.

[44]  N. Reiling,et al.  Frizzled1 is a marker of inflammatory macrophages, and its ligand Wnt3a is involved in reprogramming Mycobacterium tuberculosis‐infected macrophages , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  N. Sims,et al.  GP130 cytokines and bone remodelling in health and disease. , 2010, BMB reports.

[46]  B. Rouse.  Faculty Opinions recommendation of Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. , 2010 .

[47]  B. Pulendran,et al.  Activation of β-Catenin in Dendritic Cells Regulates Immunity Versus Tolerance in the Intestine , 2010, Science.

[48]  Yuichi Akasaki,et al.  Sfrp5 Is an Anti-Inflammatory Adipokine That Modulates Metabolic Dysfunction in Obesity , 2010, Science.

[49]  A. Pradeep,et al.  Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[50]  T. Martin,et al.  Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. , 2010, The Journal of clinical investigation.

[51]  N. Todd,et al.  Mechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis , 2008, The Journal of Immunology.

[52]  C. Evers,et al.  Box 2 Region of the Oncostatin M Receptor Determines Specificity for Recruitment of Janus Kinases and STAT5 Activation* , 2008, Journal of Biological Chemistry.

[53]  F. Dell’Accio,et al.  Identification of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signaling after injury and in osteoarthritis. , 2008, Arthritis and rheumatism.

[54]  M. Kurrer,et al.  Wnt5A/CaMKII Signaling Contributes to the Inflammatory Response of Macrophages and Is a Target for the Antiinflammatory Action of Activated Protein C and Interleukin-10 , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[55]  U. Lerner,et al.  Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms. , 2007, The Journal of endocrinology.

[56]  Holger Heine,et al.  The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. , 2006, Blood.

[57]  B. Neel,et al.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.

[58]  L. Hofbauer,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[59]  U. Lerner,et al.  IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.

[60]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[61]  K. Lindpaintner,et al.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease , 2002, Journal of medical genetics.

[62]  Mark L. Johnson,et al.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.

[63]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[64]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[65]  P. Heinrich,et al.  Non-redundant Signal Transduction of Interleukin-6-type Cytokines , 2000, The Journal of Biological Chemistry.

[66]  P. Heinrich,et al.  Signal Transduction of IL-6, Leukemia-Inhibitory Factor, and Oncostatin M: Structural Receptor Requirements for Signal Attenuation1 , 2000, The Journal of Immunology.

[67]  A. Miyajima,et al.  Receptor Subunit-specific Action of Oncostatin M in Hepatic Cells and Its Modulation by Leukemia Inhibitory Factor* , 2000, The Journal of Biological Chemistry.

[68]  G. Lisignoli,et al.  Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL‐11, leukaemia inhibitory factor and oncostatin M , 2000, Clinical and experimental immunology.

[69]  P. Heinrich,et al.  The Cytoplasmic Tyrosine Motifs in Full-Length Glycoprotein 130 Have Different Roles in IL-6 Signal Transduction1 , 2000, The Journal of Immunology.

[70]  J. Tavernier,et al.  Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. , 1999, Journal of immunology.

[71]  C. O’Brien,et al.  STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.

[72]  T. Martin,et al.  Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors , 1995, The Journal of experimental medicine.

[73]  G. Todaro,et al.  Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[74]  R. Jilka.  Parathyroid hormone-stimulated development of osteoclasts in cultures of cells from neonatal murine calvaria. , 1986, Bone.